Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and 10x Genomics (TXG)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM – Research Report) and 10x Genomics (TXG – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Insmed (INSM)
In a report issued on February 20, Eliana Merle from Barclays maintained a Buy rating on Insmed, with a price target of $231.00. The company’s shares closed last Friday at $164.91.
According to TipRanks.com, Merle is a 4-star analyst with an average return of
Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $217.71, implying a 37.5% upside from current levels. In a report issued on February 6, Evercore ISI also maintained a Buy rating on the stock with a $208.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
10x Genomics (TXG)
In a report issued on February 20, Luke Sergott from Barclays maintained a Buy rating on 10x Genomics, with a price target of $22.00. The company’s shares closed last Friday at $18.88.
According to TipRanks.com, Sergott is a 1-star analyst with an average return of
Currently, the analyst consensus on 10x Genomics is a Moderate Buy with an average price target of $19.67, implying a 2.7% upside from current levels. In a report issued on February 13, Canaccord Genuity also maintained a Buy rating on the stock with a $22.00 price target.
